
    
      The treatment indication is for chronic, diabetic foot ulcers (DFUs) between 1cm2 and 15cm2
      located below the malleoli on the plantar or dorsal surface of the foot. Patients must have
      confirmed Type I or Type II Diabetes.

      Patients will receive treatment every week for 12 weeks duration in the Single-Blind
      Treatment phase of the trial.

      Patients who receive Grafix® or control will be evaluated for primary efficacy up to 84 days,
      and for safety and wound re-occurrence for 84 days after wound closure. Patients in the
      control group whose wounds are not closed at the end of treatment may be offered Grafix® in
      an Open-Label Treatment phase. The Open-Label Treatment phase can last up to an additional 84
      days.
    
  